TriangleFOR PATIENTS · SOURCE READING
Treatment of Essential Thrombocythemia
Source: Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Treatment of essential thrombocythemia in patients younger than 60 years who have no signs or symptoms and an acceptable platelet count is usually watchful waiting. Treatment of other patients may include:
Source links and citations
chemotherapy (hydroxyurea)
Source links and citations
immunotherapy (interferon alfa or pegylated interferon alpha)
Source links and citations
anagrelide
Source links and citations
Learn more about these treatments in the Treatment Option Overview.
Source links and citations
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice